185 related articles for article (PubMed ID: 22840351)
61. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.
Nyame YA; Elshafei A; Greene DJ; Arora HC; Given RW; Tay KJ; Polascik TJ; Ross AE; Mouraviev VB; Lugnani F; Jones JS
J Endourol; 2017 May; 31(5):497-501. PubMed ID: 28437170
[TBL] [Abstract][Full Text] [Related]
62. Perineal salvage prostatectomy for radiation resistant prostate cancer.
van der Poel HG; Beetsma DB; van Boven H; Horenblas S
Eur Urol; 2007 Jun; 51(6):1565-71; discussion 1572. PubMed ID: 16949728
[TBL] [Abstract][Full Text] [Related]
63. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
64. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience.
de la Taille A; Hayek O; Benson MC; Bagiella E; Olsson CA; Fatal M; Katz AE
Urology; 2000 Jan; 55(1):79-84. PubMed ID: 10654899
[TBL] [Abstract][Full Text] [Related]
65. Salvage external beam radiotherapy for recurrent prostate adenocarcinoma after high-intensity focused ultrasound as primary treatment.
Munoz F; Guarneri A; Botticella A; Gabriele P; Moretto F; Panaia R; Ruggieri A; D'Urso L; Muto G; Filippi AR; Ragona R; Ricardi U
Urol Int; 2013; 90(3):288-93. PubMed ID: 23364287
[TBL] [Abstract][Full Text] [Related]
66. Salvage focal cryosurgery may delay use of androgen deprivation therapy in cryotherapy and radiation recurrent prostate cancer patients.
Kongnyuy M; Berg CJ; Kosinski KE; Habibian DJ; Schiff JT; Corcoran AT; Katz AE
Int J Hyperthermia; 2017 Nov; 33(7):810-813. PubMed ID: 28540788
[TBL] [Abstract][Full Text] [Related]
67. Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study.
Mizowaki T; Aoki M; Nakamura K; Yorozu A; Kokubo M; Karasawa K; Kozuka T; Nakajima N; Sasai K; Akimoto T
J Radiat Res; 2015 Jul; 56(4):750-6. PubMed ID: 25910489
[TBL] [Abstract][Full Text] [Related]
68. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
69. Treatment of prostate cancer local recurrence after whole-gland cryosurgery with frameless robotic stereotactic body radiotherapy: initial experience.
Quarrier S; Katz A; Haas J
Clin Genitourin Cancer; 2013 Jun; 11(2):89-93. PubMed ID: 23063579
[TBL] [Abstract][Full Text] [Related]
70. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
71. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome.
Ng CK; Moussa M; Downey DB; Chin JL
J Urol; 2007 Oct; 178(4 Pt 1):1253-7; discussion 1257. PubMed ID: 17698104
[TBL] [Abstract][Full Text] [Related]
72. Outcomes of salvage radical prostatectomy following more than one failed local therapy.
Sivaraman A; Scardino P; Eastham J
Investig Clin Urol; 2018 May; 59(3):152-157. PubMed ID: 29744471
[TBL] [Abstract][Full Text] [Related]
73. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
74. The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy.
Ishikawa H; Higuchi K; Kaminuma T; Takezawa Y; Saito Y; Etsunaga T; Maruo K; Kawamura H; Kubo N; Nakano T; Kobayashi M
J Radiat Res; 2020 Nov; 61(6):908-919. PubMed ID: 32888035
[TBL] [Abstract][Full Text] [Related]
75. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
76. Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre's experience.
Philippou P; Yap T; Chinegwundoh F
Urol Int; 2012; 88(2):137-44. PubMed ID: 22285952
[TBL] [Abstract][Full Text] [Related]
77. Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy--a secondary analysis of irish clinical oncology research group 97-01.
Mydin AR; Dunne MT; Finn MA; Armstrong JG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):101-8. PubMed ID: 22658512
[TBL] [Abstract][Full Text] [Related]
78. Salvage cryosurgery for locally recurrent prostate cancer after primary cryotherapy.
Chang X; Liu T; Zhang F; Zhao X; Ji C; Yang R; Gan W; Zhang G; Li X; Guo H
Int Urol Nephrol; 2015 Feb; 47(2):301-5. PubMed ID: 25510358
[TBL] [Abstract][Full Text] [Related]
79. Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml.
Umezawa R; Ariga H; Ogawa Y; Jingu K; Matsushita H; Takeda K; Fujimoto K; Sakayauchi T; Sugawara T; Kubozono M; Narazaki K; Shimizu E; Takai Y; Yamada S
Radiat Oncol; 2011 Nov; 6():150. PubMed ID: 22053922
[TBL] [Abstract][Full Text] [Related]
80. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.
Kupelian PA; Buchsbaum JC; Patel C; Elshaikh M; Reddy CA; Zippe C; Klein EA
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):704-11. PubMed ID: 11849793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
